AMRA Medical

07/05/2026

Can MSK MRI help drive impact in population health? Come find out at ISMRM 2026!

AMRA is looking forward to touching down in Cape Town this weekend to take part in the 2026 edition of the ISMRM Annual Meeting, which runs from May 9-14! We are especially excited given that on Saturday, May 9, AMRA’s own Per Widholm will deliver an invited lecture during the “History of MSK MRI: Past, Present, and Future” session. His talk, “Future: Role of MSK MRI in population health,” addresses the need for a shift in clinical MSK MRI practice.

Per will discuss how a transition toward using standardized and reproducible quantitative biomarkers, like those developed by AMRA, will be an important part of introducing a population health perspective within MSK MRI.

We’re excited to be part of the conversation and hope to see you in Cape Town! If you will be at the conference and want to get in touch, make sure to tune into Per’s session, and feel free to reach out to connect with our team onsite featuring Andrea Robina and Per Widholm, or contact us at info@amramedical.com.

We hope to see you there!

06/05/2026

What happens to muscle composition following bariatric surgery?

The AMRA team is heading to Istanbul for the 33rd European Congress on Obesity to share findings from a study using our MRI-based muscle biomarkers to quantify and assess longitudinal changes in muscle composition among adults with obesity undergoing metabolic surgery.

Researchers from AMRA, alongside our collaborators at the University of California San Diego, the University of Wisconsin-Madison, and Regeneron investigated muscle composition changes in 98 participants. The results showed that while surgery leads to an overall reduction in muscle mass, it also improves muscle quality through decreased fat infiltration. Most muscle volume loss occurred within the first 12 weeks and plateaued by one year, with signs of recovery relative to body weight over time.

The study, titled ‘Impact of metabolic surgery on muscle composition: A longitudinal MRI study’ will be shared during an oral presentation by AMRA’s Chief Scientific Officer, Dr. Jennifer Linge, featured as a “Hot Topics” abstract during the T4 Session on May 14th from 11:30 - 13:00.

If you’ll be in Istanbul for ECO 2026, make sure to tune into our presentation and connect with Jennifer Linge, Leanna Kellerman and Nicklas Weman onsite to learn more about our science!

Read more about the study here: https://amramedical.com/what-happens-to-muscle-composition-following-bariatric-surgery-amra-medical-to-share-findings-at-the-33rd-european-congress-on-obesity/

30/04/2026

AMRA Medical is gearing up for the 33rd European Congress on Obesity (ECO 2026) in Istanbul from May 12th-15th!

Our team is looking forward to again contributing to the conversation and sharing our latest findings regarding muscle composition in obesity!

Don’t miss our oral presentation, “Impact of metabolic surgery on muscle composition: A longitudinal MRI study.” Presented by AMRA’s Chief Scientific Officer, Dr. Jennifer Linge, the session will be featured as a “Hot Topics” abstract during the T4 Session on May 14th from 11:30–13:00.

Reach out to Leanna Kellerman and Nicklas Weman via info@amramedical.com if you’re interested in learning more about how AMRA’s MRI-based biomarkers are helping clinical trials assess treatment effects in obesity and metabolic disease. We can’t wait to see you in Istanbul for this important event!

28/04/2026

Are you in Switzerland this week for the 25th BioPharma Clinical Trials Nexus Conference?

Make sure to connect with Leanna Kellerman, Chief Globalization Officer at AMRA Medical, who will be onsite in Zurich!

This event brings together senior leaders across pharma and biotech to drive meaningful dialogue around the future of clinical trials; from innovation in study design to new approaches shaping clinical development.

If you’re attending the Nexus, connect with Leanna to exchange ideas and explore how AMRA’s advanced MRI-based fat and muscle biomarkers can support smarter, more efficient clinical trials.

23/04/2026

New AMRA Research Assessing the Impact of AMC in CKD Published in Clinical Journal of the American Society of Nephrology!

AMRA Medical researchers recently set out to answer the question: does muscle composition identify high-risk individuals with chronic kidney disease? The answer showed that adverse muscle composition (AMC), characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD).

Over a mean follow-up period of 3.6 years, individuals with CKD and AMC showed a markedly increased risk of all-cause mortality, with an unadjusted hazard ratio of 6.17. Importantly, this association remained significant even after adjusting for demographic, lifestyle, and clinical factors, with a hazard ratio of 4.21.

These findings highlight AMC as a clinically meaningful phenotype, enabling broader stratification of high-risk individuals and supporting the value of MRI-based muscle biomarkers in clinical trials across chronic diseases.

Read the full release from AMRA: https://amramedical.com/does-muscle-composition-identify-high-risk-individuals-in-chronic-kidney-disease-new-amra-medical-study-says-yes-reveals-strong-link-to-mortality/

21/04/2026

Job Opportunity!!
We are looking for a temporary replacement for our Office Coordinator, who will be on parental leave during the period June 2026–August 2027. You are responsible for administrative tasks related to workplace wellbeing and maintaining order at our head office in Linköping. You are the main point of contact for office-related matters, both internally and for external partners.

👉 Read more here: https://amramedical.teamtailor.com/jobs/7554215-office-coordinator-till-amra-medical

17/04/2026

What an amazing Day Two we’ve had here at the 3rd Annual GLP-1-Based Therapeutics Summit! The sessions expanded the conversation beyond cardiometabolic disease, highlighting just how quickly the therapeutic horizon for GLP-1s is evolving.

A major theme throughout the day was about exploring the potential of GLP-1-based therapies in areas such as neurodegenerative disease, aging, addiction, and women’s health, reinforcing the growing idea that these therapies may extend their benefit beyond weight loss into new disease areas.

The day concluded with a forward-looking perspective: GLP-1 therapies are no longer confined to diabetes or obesity. Instead, they are emerging as a foundational platform for a new generation of treatments, where personalization and expanded applications will define the next wave of innovation.

“What stood out from this meeting is how the conversation has shifted towards what these therapies can do beyond weight loss and importantly, how well we can measure their effects, " says AMRA’s Chief Globalization Officer, Leanna Kellerman. “This is something that AMRA has kept in mind as we continue to pioneer development of MRI-based methods and measures for metabolic research and beyond, and we couldn’t be more excited about the future of the field after this conference.”

Want to connect with AMRA to learn more about how we’re reshaping MRI-based biomarkers for metabolic disease research? Reach out to us at info@amramedical.com.

15/04/2026

AMRA has wrapped up Day One at the 3rd Annual GLP-1-Based Therapeutics Summit here in Boston, and today has made one thing clear: we’ve officially moved beyond the first wave of GLP-1 success into a far more complex and competitive phase of innovation!

Across sessions, conversations centered on combination therapies, expanding into new indications like kidney and liver disease, and unlocking broader clinical impact through more personalized approaches.

Importantly, the discussion on Day One shifted toward how we evaluate these therapies. A key highlight was AMRA’s session, “Reshaping the Standard: MRI Muscle Composition for Treatment Evaluation and Differentiation in Metabolic Disease and Beyond,” presented by CSO Dr. Jennifer Linge. Drawing on nearly two decades of research, the session highlighted how AMRA’s standardized MRI muscle biomarkers enable consistent, interpretable assessment of muscle composition. Central to this was the use of weight- and BMI-invariant muscle volume Z-Scores, which uncover treatment effects independent of body weight. As therapies continue to drive significant weight loss, these insights are becoming critical to understanding true treatment effects, individual response, and opportunities for differentiation across GLP-1 therapies.

Stay tuned to find out what we learn from tomorrow’s highly-anticipated Day Two! If you’re in Boston this week for the Summit and would like to connect with AMRA onsite, reach out to us at info@amramedical.com.

09/04/2026

We are so excited to see the launch of the new Industry Collaborative from the FSHD Society, in collaboration with SOLVE FSHD and the FSHD Clinical Trial Research Network!

This new initiative aims to bring together stakeholders across industry & academia to improve how clinical trials in FSHD are designed, executed, and evaluated.

Here at AMRA, we’re proud to support this effort by contributing our experience in applying quantitative MRI to neuromuscular diseases, including FSHD. For the last decade, we’ve worked alongside collaborators in the field to help develop standardized, global multi-site imaging approaches enabling consistent, high-quality data generation across trials and geographies.

We’re looking forward to seeing how this collaborative effort advances the field and contributes to more efficient and informative clinical trials in FSHD!

⬇️ Read the full release from the FSHD Society below.

“Access to high-quality clinical trial and natural history data is critical for improving trial design for rare diseases. This research collaboration creates a rigorous framework for generating insights that individual FSHD programs cannot achieve in isolation.”

We're excited to announce our collaboration with Solve FSHD and the FSHD Clinical Trial Research Network to speed the delivery of effective treatments to individuals living with FSHD.

Read the full press release: https://www.fshdsociety.org/2026/04/08/industry-collab-launch/

12/03/2026

Be sure to stop by today’s poster sessions if you are at ICFSR 2026!

Hanna Heering, MScEng will be presenting Poster No. 184: “Can normative data for muscle ageing be inferred from cross-sectional cohort data? A large scale investigation using longitudinal UK Biobank imaging data” in the Sarcopenia category.

AMRA’s CSO, Dr. Jennifer Linge, will also be presenting Poster No. 178: “Muscle abnormalities in heart failure detected using MRI-based muscle composition”.

We’re excited to be part of the conversation around advancing muscle research and look forward to discussing how MRI-based muscle composition biomarkers can support studies in sarcopenia, muscle wasting, and beyond.

Read more about AMRA at ICFSR 2026 here -> https://amramedical.com/catch-the-latest-amra-research-on-muscle-composition-aging-and-heart-failure-icfsr-2026/

11/03/2026

Are you attending the ICFSR Conference in Washington this week?

Make sure to stop by the Thursday, March 12th poster session to see Dr. Jennifer Linge, CSO at AMRA, present Poster No. 178: “Muscle abnormalities in heart failure detected using MRI-based muscle composition” in the Sarcopenia category.

Our team onsite is looking forward to connecting with the community and discussing how advanced MRI-based muscle assessment biomarkers can deepen our understanding of muscle composition in sarcopenia and frailty research.

Read more about AMRA at ICFSR 2026 here -> https://amramedical.com/catch-the-latest-amra-research-on-muscle-composition-aging-and-heart-failure-icfsr-2026/